Ways of Regulating Drugs in the 19th and 20th Centuries

Edited by

Jean-Paul Gaudilliére
Director, CERMES3, CNRS, Paris

and

Volker Hess
Chair of the Institute for the History of Medicine, Charité University Medicine Berlin

This volume is part of the activities of the European Science Foundation Research Networking Programme DRUGS.
Contents

List of Tables ix
List of Figures x
Notes on Contributors xi

General Introduction
Jean-Paul Gaudillière and Volker Hess 1

1 Secrets, Bureaucracy, and the Public: Drug Regulation in Early 19th-Century Prussia 17
Volker Hess

Axel C. Hüntelmann

3 Professional and Industrial Drug Regulation in France and Germany: The Trajectories of Plant Extracts 66
Jean-Paul Gaudillière

4 Making Risks Visible: The Science, Politics, and Regulation of Adverse Drug Reactions 97
Harry M. Marks

5 Regulating Drugs, Regulating Diseases: Consumerism and the US Tolbutamide Controversy 121
Jeremy A. Greene

6 Thalidomide, Drug Safety Regulation, and the British Pharmaceutical Industry: The Case of Imperial Chemical Industries 151
Viviane Quirke

7 What's in a Pill? On the Informational Enrichment of Anti-Cancer Drugs 181
Alberto Cambrosio, Peter Keating, and Andrei Mogoutov

8 Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer 206
Ilana Löwy
Contents

9 AZT and Drug Regulatory Reform in the Late 20th-Century US  
Donna A. Messner  228

10 Professional, Industrial, and Juridical Regulation of Drugs: The  
1953 Stalinston Case and Pharmaceutical Reform in Postwar France  
Christian Bonah  245

11 Managing Double Binds in the Pharmaceutical  
Prescription Market: The Case of Halcion  
Toine Pieters and Stephen Snelders  270

12 Pharmaceutical Patent Law In-the-Making: Opposition and  
Legal Action by States, Citizens, and Generics Laboratories  
in Brazil and India  
Maurice Cassier  287

Index  319